恶性肿瘤患者应用吉西他滨化疗对凝血功能的影响

Effects of Gemcitabine on the Coagulation Function of Patients with Malignant Tumor

目的:观察恶性肿瘤患者应用吉西他滨化疗后对凝血功能的影响。方法:回顾性分析在2010年1月至2012年12月期间,在我科进行以吉西他滨单药或联合化疗、引起血小板减少(Ⅲ°或Ⅳ°)的34名恶性肿瘤患者的临床资料,观察化疗对其出血表现和凝血功能的影响。结果:在34例患者中,血小板减少Ⅲ°有20例,血小板减少Ⅳ°有14例。12例患者发生出血表现,其中4例伴消化道出血。34例患者凝血功能在化疗前后无明显影响,差异无统计学意义(P>0.05)。结论:以吉西他滨单药或联合化疗治疗恶性肿瘤患者,虽然可能导致血小板减少Ⅲ°至Ⅳ°,但凝血功能未受到影响,具有出血临床表现的患者给予相应的治疗后未出现严重后果,吉西他滨可以在监测血常规的情况下使用。

Objective： To investigate the effects of gemcitabine on the function of blood coagulation of patients with malignant tumor. Methods：Clinical data of 34 patients with malignant tumor treated with gemcitabine and got III° or IV° thrombocytopenia in our hospital from Jun, 2010 to Dec, 2012 were retrospectively analyzed. The effects of gemcit-abine on the hemorrhage and change of coagulation time of patients were observed. Results：Twenty out of total 34 patients suffered from Ⅲ°thrombocytopenia , while other 14 suffered from Ⅳ° thrombocytopenia. Hemorrhage was observed in 12 patients including 4 cases of digestive tract hemorrhage. In all 34 cases, the coagulation function of patients didn’ t change obviously before and after chemotherapy （P〉0. 05）. Conclusion：Although III° or IV° thrombocytopenia may be found in the patients with malignant tumor who were treated with chemotherapy regimen contained gemcitabine, the coagulation func-tion was not affected. After proper treatment, the patients getting hemorrhage didn’ t come out serious consequence. Thus, it is acceptable to use gemcitabine when blood routine can be monitored for the treatment of cancer patients.